Novel Antischizophrenia Treatments
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with r...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2012.
|
| Σειρά: | Handbook of Experimental Pharmacology,
213 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Preface
- Clinical instruments to evaluate and guide treatment in schizophrenia
- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders
- Nicotinic mechanisms in psychotic disorders
- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia
- Inhibitors of glycine transport as potential new treatments in schizophrenia
- The role of glutamate in schizophrenia
- Metabotropic glutamate receptors as targets for new treatments in schizophrenia
- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions
- Phosphodiesterase inhibitors as potential new treatments in schizophrenia
- Disease modifying approaches to schizophrenia
- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia
- Transgenic animals reflecting aspects of schizophrenia
- Behavioral animal models of pro-cognitive treatments for schizophrenia. .